AKT1 and renal carcinoma: The use of CRISPR/Cas9-mediated knockout to target ELOVL5 inhibits AKT Ser473 phosphorylation and suppresses renal cancer cell invasion by downregulating chemokine (C–C motif) ligand-2 through the AKT-mTOR-STAT3 signaling pathway [44].